newsfilter
← Latest News
GlobeNewswire·

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

- Phase 2b ODYSSEY Trial in Wet AMD Remains on Track with Topline Data Expected in Late Q3 2024 - - ODYSSEY Safety Review Committee Recommends Trial Continue as Planned with no Serious Adverse Events Observed - -